Total pharma industry M&A deals in May 2019 worth $2.83bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 15.1% over the previous month and a drop of 78.6% when compared with the last 12-month average of $13.18bn.
The US held a 30.1% share of the global pharma industry M&A deal value that totalled $9.4bn in May 2019.
In terms of deal activity, the US recorded 20 deals during May 2019, marking a decrease of 4.8% over the previous month and a drop of 5.3% over the 12-month average.
The US pharma industry M&A deals in May 2019: Top deals
The top five pharma industry M&A deals accounted for 98.3% of the overall value during May 2019.
The combined value of the top five pharma industry M&A deals stood at $2.78bn, against the overall value of $2.83bn recorded for the month. The top announced pharma industry M&A deal tracked by GlobalData in May 2019 was Merck &Inc’s $2.2bn acquisition of Peloton Therapeutics.
In second place was the $400m acquisition of Abide Therapeutics by H. Lundbeck and in third place was Evotec‘s $90m acquisition of Just Biotherapeutics.
The $58m asset transaction with Merrimack Pharmaceuticals by 14ner Oncology and Ligand Pharmaceuticals‘ asset transaction with Novan for $32m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.